Article
Risk of failure in patients with 215 HIV-1 revertants starting their first thymidine analog-containing highly active antiretroviral therapy.
AIDS (London, England) - 23 Jan 2004
Violin Michela, Cozzi-Lepri Alessandro, Velleca Rossella, Vincenti Antonella, D'Elia Salvatore, Chiodo Francesco, Ghinelli Florio, Bertoli Ada, d'Arminio Monforte Antonella, Perno Carlo Federico, Moroni Mauro, Balotta Claudia
Abstract excerpt
OBJECTIVE: To investigate the impact of 215 HIV-1 revertants on the risk of virological failure of the first thymidine analog-containing highly active antiretroviral therapy (HAART). DESIGN: The study included 491 HIV-1 subjects of the Italian Cohort Naive for Antiretrovirals, 405 of whom received a genotypic assay before therapy and had a virological follow-up. METHODS: Pre-treatment genotypic resistance was...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.